Get to know our clinical trials

Clinical trial of AMG 509 in subjects with metastatic castration-resistant prostate cancer

THE AIM OF THIS STUDY IS TO OBTAIN MORE INFORMATION ABOUT AMG 509 IN MONOTHERAPY (SINGLE DRUG) AND AMG 509 IN COMBINATION WITH ABIRATERONE OR ENZALUTAMIDE OR PEMBROLIZUMAB IN PEOPLE WITH MCRPC. IT WILL TEST WHETHER ADMINISTRATION OF AMG 509 ALONE OR AMG 509 IN COMBINATION WITH ABIRATERONE OR ENZALUTAMIDE OR PEMBROLIZUMAB IS SAFE AND TOLERABLE AND WHETHER IT CAUSES ANY SIDE EFFECTS. THIS STUDY WILL ALSO EVALUATE WHICH DOSES OF AMG 509 ALONE AND AMG 509 IN COMBINATION WITH ABIRATERONE OR ENZALUTAMIDE OR PEMBROLIZUMAB ARE SAFE FOR ADMINISTRATION IN PEOPLE AND HOW IT AFFECTS MCRPC.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF AMG 509 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
  • Code EudraCT: 2021-005052-11
  • Protocol number: 20180146
  • Promoter: Amgen, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.